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ABSTRACT

ARTICLE HISTORY

Solid lipid nanoparticles (SLNs) are very potential formulations for topical delivery of antifungal drugs.
Hence, the purpose of this research was to formulate the well-known antifungal agent Fluconazole
(FLZ)-loaded SLNs topical gel to improve its efficiency for treatment of Pityriasis Versicolor (PV). FLZSLNs were prepared by modified high shear homogenization and ultrasonication method using different concentration of solid lipid (Compritol 888 ATO, Precirol ATO5) and surfactant (Cremophor RH40,
Poloxamer 407). The physicochemical properties and the in vitro release study for all FLZ-SLNs were
investigated. Furthermore, the optimized FLZ-SLN formula was incorporated into gel using Carpobol
934. A randomized controlled clinical trial (RCT) of potential batches was carried out on 30 well diagnosed PV patients comparing to market product CandistanV 1% cream. Follow up was done for
4 weeks by clinical and KOH examinations. The results showed that FlZ-SLNs were almost spherical
shape having colloidal sizes with no aggregation. The drug entrapment efficiency ranged from 55.49%
to 83.04%. The zeta potential values lie between 21 and 33 mV presenting good stability. FLZ
showed prolonged in vitro release from SLNs dispersion and its Carbapol gel following Higuchi order
equation. Clinical studies registered significant improvement (p < .05) in therapeutic response (1.4-fold;
healing%, 4-fold; complete eradication) in terms of clinical cure and mycological cure rate from PV
against marketed cream. Findings of the study suggest that the developed FLZ loaded SLNs topical
gels have superior significant fast therapeutic index in treatment of PV over commercially available
CandistanV cream.
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Introduction
Fluconazole (FLZ) is a third generation triazole antifungal
drug with broad spectrum activity against systemic and
superficial fungal infections (Ruhnke et al., 2008; AbdelMottaleb et al., 2009). It acts by preventing production of
vital elements in the fungal membrane as ergosterol by
inhibiting the fungal cytochrome P-450 enzyme (Nicky
et al., 2008). This inhibition action on cytochrome P-450
enzymes was found to be greater in fungal species in contrast to mammalian enzyme, which improve the safety profile of triazoles (Koltin & Hitchcock, 1997). FLZ is slightly
soluble in water (5 mg/mL at 37  C), with molecular weight
of 306.3 Da and has a pKa value of 3.7 (weak base) (Alekha
& William, 2006; Bidkar et al., 2007). It is presented as oral
and parenteral dosage forms which can be associated with
serious side effects as stomach upset, diarrhea, feeling sick,
vomiting, rash, and reduction in red blood cells. In addition,

there is incidence of hepatotoxicity in patients receiving triazoles (Song & Deresinski, 2005). Therefore, trying to
develop topical pharmaceutical dosage forms of FLZ is
highly indicated to avoid such adverse events (Gupta et al.,
2010).
The drug delivery onto the skin is recognized as an effective
means of local therapy for many dermatologic diseases (Kaur &
Guleri, 2013). But the main obstacle facing the efficiency of
topical antifungal drugs is the ability to penetrate the skin
powerfully. Accordingly, the active material should pass in
effective concentration through the stratum corneum, the first
layer of the skin, to reach target tissue. Researchers may
depend on pharmaceutical formulations as they exert a key
role for permeation of drugs into skin. Development of novel
approaches for local therapy of skin fungal infections utilizes
advanced carrier systems for numerous compounds (Lee &
Maibach, 2006). Nanoparticles are usually produced from natural/synthetic polymers with size range between 10 and
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1000 nm. Therefore, they are suitable to optimize topical drug
delivery and reduce toxicity (Mukherjee et al., 2009).
The nanoparticulate carrier systems as solid lipid nanoparticles (SLNs) has gained interest for the local therapy of skin
fungal infection as they aid the permeation of loaded active
materials through the stratum corneum layer (Gupta & Vyas,
2012). SLNs are colloidal carriers developed as an updating
system to the ordinary used carriers as micro-emulsions and
liposomes, as the liquid lipid (oil) has been substituted by a
solid lipid. Hence, lots of unique properties have been linked
to SLNs as small size, large surface area, high drug loading,
and the interaction of phases at the interfaces, and improve
performance of pharmaceuticals, neutraceuticals, and other
materials (Cavalli et al., 1993).
Pityriasis versicolor (PV), also known as tinea versicolor, is
a superfacial fungal infection caused by proliferation of
Malassezia species in the stratum corneum layer of skin.
Malassezia acquires a pathogenic potential when assuming
the mycelial form under the influence of trigger factors
including, humidity, immunosuppression, and hyperhidrosis
(Karakas et al., 2005). Accordingly, PV is mostly common in
humid weathers as compared to calm weathers (CrespoErchiga & Florencio, 2006). Indeed, the yeast most often
becomes pathogenic in tropical climates, infecting up to
30–40% of the population in those areas (Faergemann, 1995).
Cure rate from PV is hard, as relapse after treatment can be
occur within 2 years (Faergemann, 1999). PV is presented
with well-defined round or egg-shaped macules on the
upper arms, trunk, and neck as the concentration of sebaceous glands is great; they can be white, erythematous, or
brown (Mellen et al., 2004). PV appears frequently in adolescents (Dutta et al., 2002; Morais et al., 2010; Framil et al.,
2011). The main concern for patients is their looking for
treatment for the unpleasant appearance of the skin (Gupta
et al., 2002). The topical antifungal agents are found to be
quite satisfactory in the treatment of PV fungal infections,
however, systemic antifungals are recommended for severe
or recalcitrant cases (Hald et al., 2015). On the other hand,
several non-specific topical treatments are used in treating
PV (Gupta et al., 2004, 2005). Sometime, misdiagnosis may
lead to wrong and unsuccessful treatment for example with
antibiotics, corticosteroids (Mellen et al., 2004).
Improving the permeation of the antifungal agents to the
dermis layer of skin is desired as fungi hyphae (mycelium) can
€ller-Goymann,
enter deeply through the epidermal layers (Mu
2004). Thus, topical application of SLNs based gel with
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increased penetration and retention through skin because of
lipid nano-formulation will be much promising for the topical
treatment of fungal infections and symptomatic relief.
Therefore, the aim of the current study was to develop
and to evaluate FLZ loaded-SLNs based gel for topical treatment of Pityriasis Versicolor. In addition, the golden goal of
the research was to investigate clinically the efficacy of the
prepared FLZ-SLNs gel compared to the antifungal topical
formulation currently available in the market for topical treatment of patients with PV.

Materials and methods
Flucoazole, Cremophor RH 40V (HLB 14–16), Poloxamer 407
and Carbapol 934, were kindly supplied by Egyptian
International Pharmaceutical Industries Company (E.I.P.I.Co)
(10th of Ramadan City, Egypt). Compritol 888 ATO (glyceryl
behenate) and pricerol ATO5 (glyceryl palmitostearate), were
kindly gifted from Gattefosse Co. (Lyon, France). Absolute
Ethanol, potassium dihydrogen phosphate and disodium
hydrogen phosphate were purchased from Sigma-Aldrich
Company (St. Louis, MO). All the other chemicals were of
analytical grade.
R

Preparation of solid lipid nanoparticles loaded with FLZ
The modified high shear homogenization and ultrasonication
method has been used for preparation of eight formulae of
FLZ-SLNs (Priyanka & Sathali, 2012). Lipids (Compritol 888
ATO or Precirol ATO5) were heated by 50  C above their
melting points. Then after 1% w/w FLZ was added to the
lipid matrix to obtain a drug-lipid mixture. While the aqueous
phase was obtained by dissolving the surfactant (Poloxamer
407 or Cremophor RH 40) in deionized water and heated up
to the temperature of the melted lipid phase. Afterward, the
melted lipid phase was poured onto the warm aqueous
phase then homogenization was started at 21,000 rpm for
10 min with homogenizer (Silent Crusher Homogenizer,
Heidolph Instruments, Germany). The obtained pre-emulsion
was ultrasonicated using digital ultrasonic sonicator (Model
SH150-4L, MTI Corporation, Richmond, CA) for 30 min. FLZ
loaded SLNs were finally obtained by allowing the hot nanoemulsions to cool to room temperature, forming lipid nanoparticles. Table 1 reports the composition of the prepared
SLNs dispersion loaded with FLZ. In addition, blank solid lipid

Table 1. Composition of SLNs loaded with Fluconazole and FLZ-SLNs topical gels (% w/w).
FLZ-SLNs dispersions(% w/w)a

FLZ-SLNs topical gels (% w/w)a

Formulation code Compritol 888 ATO Precirol ATO5 Poloxamer 407 Cremophor RH40 Carpobol 934 Methyl Paraben TEAb Distilled water Up to Gel code
SLN 1
SLN2
SLN 3
SLN 4
SLN 5
SLN 6
SLN 7
SLN 8
a

8
10
8
10
–
–
–
–

Fluconazole concentration is 1% w/w.
TEA: Triethanolamine.

b

–
–
–
–
8
10
8
10

0.5
0.5
–
–
0.5
0.5
–
–

–
–
0.5
0.5
–
–
0.5
0.5

–
1
–
1
–
1
–
1

–
0.1
–
0.1
–
0.1
–
0.1

–
q.s
–
q.s
–
q.s
–
q.s

–
100
–
100
–
100
–
100

–
Gel 1
–
Gel2
–
Gel 3
–
Gel4
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nanoparticles were prepared in a similar way without adding
the drug.

Formulation of FLZ-SLN topical gel
FLZ-SLNs dispersion was converted into gel carrier system
using Carbopol (CP 934) as gelling agent. 1% w/w Carbopol
934 was dissolved in distilled water, stirred for 10 min at
1500 rpm. Subsequently, calculated amount of freshly prepared FLZ-SLNs dispersion was added and mixed for 10 min,
then neutralized by drops of triethanolamine until pH 5.5.
Prepared gels were further allowed to stand overnight to
remove entrapped air (Kesharwani et al., 2016).
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Characterization of FLZ-SLNs
Determination of the entrapment efficiency percentage
(EE%)
The entrapment efficiency percentage of all prepared FLZ
SLNs was determined by measuring the concentration of free
drug in the dispersion media. Separation of free drug from
the nano lipid dispersion formulation was done by the ultracentrifugation method. Here, centrifugation of nano lipid dispersion was carried out at 14,000 rpm for 90 min using Remi
cooling centrifuge (Mumbai, India). The clear supernatant
from the resulting solution was diluted appropriately using
phosphate buffer pH 5.5 and analyzed by ultraviolet (UV)
spectrophotometer at 261 nm (Shimadzu 1800, Japan)
(Agalakshmi et al., 2014). The EE% was calculated from the
Equation (1) (Ahmed et al., 2014).


EE % ¼ ðWinitial drug  Wfree drug Þ=Winitial drug  100
(1)
Where ‘Winitial drug’ is the mass of initial drug used for the
assay and ‘Wfree drug’ is the mass of free drug detected in the
supernatant after centrifugation of the aqueous dispersion.

Particle size and zeta potential analysis
Particle size and Zeta potential was measured for selected
FLZ-SLNs formulae in folded capillary cells using zetasizer
(PCS, Malvern Mastersizer Hydro 2000G, UK). About 1 ml of
each nanodispersions was diluted with 10 ml deionized
water. Ultra sonication of the samples has been done before
size determination for 5 min (Shah et al., 2012).
Transmission electron microscope (TEM)
The shape of the selected FLZ-SLNs dispersion was determined by the transmission electron microscope (Model JEM1230, Jeol, Tokyo, Japan). One drop of diluted sample was
placed on the surface of a carbon coated copper grid, after
staining with one drop of 2% w/w aqueous solution of phosphotungestic acid. Afterward the samples were left to dry for
10 min for examination (Patel & Prajapati, 2016).
In vitro drug release studies and release kinetics
The in vitro release of FLZ from all prepared SLNs was evaluated by the dialysis bag technique (Khalil et al., 2014). FLZSLNs dispersion equivalent to 5 mg of FLZ were accurately

weighed and transferred to cellulose dialysis membrane having a molecular weight cutoff from 12,000 to 14,000 Da.
The membrane is tied with threads and immersed in 50 ml
ethanol and phosphate buffer pH 5.5. The flask was kept in
an incubator at 37  C and stirred at 50 rpm, specific volume
of the samples were withdrawn at regular intervals and equal
volume of dissolution media was added to the release
medium to replenish it. The release of FLZ from nanolipids
was determined spectrophotometrically at 261 nm using prepared plain SLNs as blank. Experiments were carried out in
triplicates. In vitro release data of FLZ from prepared SLNs
were fitted to various kinetic models and were analyzed in
order to explain the mechanism of drug release.

Differential scanning calorimetry (DSC)
The thermal characters of the prepared FLZ-SLNs were determined by DSC. In addition, DSC analyzes were performed on
pure FLZ, Compritol 888 ATO and Precirol ATO5 by a Mettler
Toledo DSC (Mettler-Toledo, Viroflay, France). About 1–2 mg
of FLZ, Compritol 888 ATO and Precirol ATO5 have been
accurately weighted in 40 ll aluminum pans. DSC scans have
been recorded at a heating rate of 100 C/min and was run
over the range 25–3000  C, using an empty pan as reference
(Castelli, 2005).
Characterization of FLZ-SLNs topical gels
Visual appearance and pH
Visual appearance, spreadability, and clarity of prepared FLZSLNs gel were observed for the presence of any particular
matter. The pH of each gel batch was determined using a pH
meter (JENWAY 350, UK). One gram of each formulated gel
was dispersed in 30 ml of distilled water, then the pH was
measured which noted by bringing the electrode near the
surface of the formulations and allowing it to equilibrate for
1 min (Kumar & Himmestein,1995; Srividya et al., 2001).
Estimation of drug content
One gram of selected FLZ-SLNs gel was taken into a standard
volumetric flask and mixed with mixture of phosphate buffer
pH 5.5: ethanol. The amount of drug per 1 g gel was determined spectrophotometrically at 261 nm after filtration
through Millipore filter (0.45 lm) and the drug content was
obtained from the calibration curve (Carlfors et al., 1998;
Nanjawade et al., 2009).
Rheological studies
The viscosity of prepared FLZ-SLNs gels was studied on
Brookfield viscometer (DV-II Pro Viscometer, Middleboro, MA)
using CPE-42 spindle. For each sample continuous variation
of the speed rate from 1 to 100 s1) then back ward from
100 to 1 s1) was applied (25 ± 1.0  C) and the resulting viscosity was measured (Wamorkar et al., 2011).
In vitro drug release studies
In vitro release of FLZ from different topical SLNs gel formulae was evaluated by using dialysis bag technique (Khalil

DRUG DELIVERY

et al., 2014) and performed in dissolution medium consists of
phosphate buffer pH 5.5 and ethanol. FLZ SLNs gel containing equivalent to 5 mg of FLZ were accurately weighed and
transferred to cellulose dialysis membrane having, molecular
weight cutoff from 12,000 to 14,000 Da then the experiment
completed as previous. The results were the mean of three
experiments. The release profiles of FLZ were evaluated by
fitting the experimental data to equations describing different kinetic orders named as zero order, first order, Higuchi,
Korsemeyer–Peppas model. The accepted order of kinetics
was based on high regression coefficient value.
Furthermore, the promising prepared FLZ-SLNs gel formula which based on in vitro release study have been chosen
for further clinical evaluation on well diagnosed thirty
patients of Pityriasis Versicolor in contrast to the commercial
antifungal topical product Clotrimazole (Candistan 1%)V Adco
company.
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Clinical study of the FLZ-SLNs topical gels
Setting
Patient selection and recruitment were carried out in
Dermatology Department, Faculty of Medicine, Tanta
University Hospitals. Thirty patients with a clinical diagnosis
of Pityriasis Versicolor were selected for the study.
Ethical approval
Written informed consent was compulsory for contribution in
the study. Necessary ethical clearance was obtained from the
ethical committee office code number: 89 Al-Azhar University
and the study was conducted in accordance with the ethical
principles that have their origin in the Declaration of Helsinki
Good Clinical Practice. The staff notified the contributors with
the objectives, dates, drugs, diet, possible risks, and general
activities through the clinical part of the study.
Patients
The current study comprised thirty male patients who
received a diagnosis of PV, and who had the following symptoms were eligible for inclusion: typical appearance of skin
lesions and confirmed by microbiological examination. While
pregnant or lactating women, those have an evidence of
human immunodeficiency virus or other life threatening
infection, having history of hypersensitivity to FLZ or
included in any other clinical trial within the previous month
will be excluded from this study. Additional exclusion criteria
included any concomitant medical condition that may have
presented unacceptable risks to the patient, as judged by the
study investigator.
Study design
This is randomized prospective controlled trial with three parallel treatment arms. Eligible patients who satisfied the inclusion criteria were randomized 1:1:1 to three treatment arms
according to a randomization list by closed envelope each
group comprising of ten PV patients.
Group I covered the PV patients treated topically with Gel
2(1% Carpobol gel containing: SLNs of 10% Compritol
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888ATO þ0.5% Cremophor RH40 þ 1% FLZ) twice daily for
4 weeks.
Group II comprised of PV patients treated topically with
Gel 3(1% Carpobol gel containing: SLNs of 10% Precirol
ATO5 þ 0.5% Ploxamer 407 þ 1% FLZ) twice daily for 4 weeks.
Group III (active control) consists of PV patients treated
topically with commercially available product, Clotrimazole
(Candistan 1%)V Edco Company twice daily for 4 weeks.
In the current study, the efficiency and safety of two
prepared 1% FLZ-SLNs topical gels in comparison to the
commercial
available
topical
Clotrimazole
namely,
CandistanV cream 1% in topical treatment of PV were
reported. Each patient visited the investigator four times
during the trial. After the baseline visit, they were asked to
report again every week for a month for follow-up to look
for any relapse.
R

R

Assessment of efficacy and safety
Following the initial (base line) visit, the subsequent visits
were scheduled on day 7, day 14, day 21, and day 30. The
efficacy and safety of the prepared gels was compared with
marketed CandistanV 1% cream for the positive clinical
response and changes from baseline for the symptoms of PV
that reported every week by clinical, visual (photographic),
and mycological examinations. The clinical parameters for
evaluation were signs and symptoms. These parameters were
assessed on a pre-determined four point scale as percentage
of recovery from PV and documented by photographic pictures which show the percentage of recovery. Clinical assessment were made and recorded by three separate
dermatologists.
The clinical examination findings were easily confirmed
with the mycological microscopic examination of skin scales
soaked in potassium hydroxide (KOH) (Thirumurthy et al.,
2002; Koneman, 2006). The affected skin area was thoroughly
wiped with 70% alcohol to remove the surface contaminants.
After drying, the active edges of the lesions were scraped
with a flame sterilized; No. 15 scalpel blade from at least two
infected areas. The specimen was placed on a glass slide,
one or two drops of 20% solution of KOH are added and a
cover slip applied. Lactophenol cotton blue stain was added
to the slide in order to examine the hyphal structure. Also,
the slide briefly heated over a flame. This process allows the
KOH to dissolve cellular material, leaving the hyphae and
spores more easily identifiable. The slides were examined
under light microscope (C x 40, 10, Olympus, Center Valley,
PA). Microscopic examination demonstrated the characteristic
thick-walled spherical or oval yeast forms and coarse septate
mycelium, often broken up into short filaments. This combination of mycelium strands and numerous spores is commonly
referred to as ‘spaghetti and meatballs’ or ‘banana and
grapes’ and are characteristic of Malassezia furfur in PV scales
(Kurade et al., 2006).
The Existing of the PV fungus, represented by the mycological microscopic examination, was categorized in three
main scales as follows:
Persistence (P): still positive microscopy appearance at follow-up visits.
R
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Persistence with improvement (PI): less density positive
microscopy appearance at follow-up visits.
Eradication (E): complete microscopic disappearance of
M. furfur in all follow up visits.

Statistical analysis
For clinical part: The data are expressed as the mean ± standard deviation. The statistical analysis was done using
SigmaPlotV 12.5 software extended with the statistical package. Two-way repeated measures analysis of variance was
used to assess the significance of the difference between
quantitative variables. p < 0.05 was considered to be statistically significant.
For mycological part: to evaluate the effect of different
treatments at different weeks on the frequencies of M. furfur
fungus degrees (P, PI, and E), pairwise comparisons were performed by Mann–Whitney U non-parametric test using IBM
SPSSV Statistics 20 software extended with the statistical
package.
R
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Results and discussion
Preparation and characterization of FLZ-SLNs
For the current study and after screening different concentration of solid lipids and surfactants by applying different
methods of preparation, FLZ-SLNs were well achieved by the
modified high shear homogenization and ultrasonication
method as the drug showed high solubility in the molten lipids. It is a very simple and reproducible method (Wei et al.,
2016).

Precirol ATO5 (mixtures of mono-, di-, and triglycerides)
form less perfect crystals with many defects proposing more
space to incorporate the drugs (Muller et al., 2000). The
results suggested that as the lipid concentration increases
from 8% to 10% w/w with constant concentrations of surfactant 0.5% w/w, the drug EE increased and this results
similar to finding of Thatipamula et al. (2011). This is due to
an incorporation of high concentration of solid lipids leads
to reduced crystallinity and increased imperfections in the
crystal lattice of lipid which leaves enough space to accommodate drug molecules (Radtke et al., 2005). Also, the
results showed that Compritol 888 ATO exhibited significance increase in EE than Precirol ATO5 (p value < .05). This
may be related to the higher hydrophobicity nature of
Compritol 888 ATO as it is composed of long chain fatty
acids that attached to the triglycerides which lead to
increase accommodation of lipophillic drugs as FLZ (Khalil
et al., 2013). Moreover, it shows high drug entrapment efficiency (EE %) may be due to the existence of large amount
of mono-, di-, and tri-glycerides that aids in drug solubilization (Manjunath et al., 2005).
Also, the results showed that there is a significance difference between the two types of surfactant (p value < .05)
which showed that Poloxamer 407 has the higher EE for all
lipids types than Cremophor RH 40 as Poloxamer 407 gave
nanoparticles a smooth surface with very few or no pores to
minimize the drug loss during the fabrication process (Pandita
et al., 2009). In addition, the decrease in %EE between different formulations may be explained by the increased solubility
of FLZ in aqueous solution when Cremophor RH 40 were used
as stabilizers (Elnaggar et al., 2015).

Particle size and polydispersity index analysis
Entrapment efficiency (EE %)
In order to achieve high drug encapsulation efficiency, many
variables were explored, including the type and concentration of both lipids and surfactants. The corresponding percentage of entrapment efficiency of FLZ-SLNs was found to
be satisfactory high which is ranging from 55.48 ± 1.21 to
82.94 ± 1.24% as depicted in Table 2. This results can be
attributed to the fact that FLZ is a moderate lipophilic drug
(Mathy et al., 2005), and thus has affinity toward lipid matrix
(Duran-Lobato et al., 2013). Moreover, this may be accredited to the structure of solid lipid used as by using highly
crystalline lipids with a perfect lattice (e.g. monoacid triglycerides) lead to drug expulsion (Westesen et al., 1997).
While, more complex lipids as Compritol 888 ATO and

FLZ loaded SLNs formulae that showed highest EE% subjected to further characterization of particle size, polydispersity index, and zeta potential as revealed in Table 2. The
tested FLZ-SLNs formulations showed a mean particle size
between 292 and 500 nm which is an optimum size for topical drug delivery (Jenning et al., 2000). FLZ-loaded SLNs, prepared with Compritol 888 ATO as the lipid matrix, resulted in
larger particle size compared to SLNs prepared using Precirol
ATO5, with all type of surfactants studied. This may be
referred to the difference in the viscosity and chain length of
the utilized lipids (Ahlin et al., 1998). Furthermore, this may
be related to the melting point of the lipid, as Compritol 888
ATO has a higher melting point (m.p. 69.0–74.0  C) than
Precirol ATO5 (m.p. 50.0–60.0  C), which lead to delay lipid

Table 2. Characterizations of selected FLZ SLNs.
Formulation code
SLN1
SLN2
SLN3
SLN4
SLN5
SLN6
SLN7
SLN8
a

EE%a

Zeta potential (mv)a

Polydispersity indexa

Mean Particle Size (nm)a

76.72 ± 1.03
82.94 ± 1.24
71.27 ± 1.11
80.52 ± 1.05
71.39 ± 1.23
79.03 ± 1.11
55.48 ± 1.21
77.04 ± 1.12

–
21 ± 2.76
–
33.1 ± 1.24
–
22.9 ± 1.66
–
25.7 ± 0.83

–
0.29 ± 0.64
–
0.255 ± 0.47
–
0.228 ± 0.52
–
0.278 ± 0.79

–
307 ± 0.32
–
500 ± 0.26
–
292 ± 0.79
–
420 ± 0.53

Values are represented as mean ± SD (n ¼ 3).
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crystallization from the hot homogenized circumstance causing growth in the particle size (Ekambaram & Sathali, 2011).
These results were in agreement with studies on cyclosporine-loaded SLNs achieved by Gokce et al. (2008). Moreover,
Khalil et al. (2014) concluded that Compritol 888 ATO and
Precirol ATO5 resulted in the largest and smallest particle
sizes, respectively, regarding the investigation of the preparation of meloxicam-loaded lipid nanoparticle-based hydrogels
for topical application.
FLZ-SLNs dispersion exhibited lower particle size when
prepared using Poloxamer 407 as stabilizer than the other
surfactant regardless the lipids used. This result may be due
to Poloxamer 407 have higher molecular weight and higher
HLB value when compared to other used surfactant
Cremophor RH40 (Jawahar et al., 2009). The polydispersity
index (PDI) is a marker of particle size distribution. The PDI
values were lower than 0.3 for all the formulations regardless
of the surfactant, lipid type. This indicates narrow size distribution which reflects the suitability of the method of preparation (Bahari & Hamishehkar, 2016).

Zeta potential analysis
Zeta potential is an important surface characterization technique which helps in determining the potential stability and
surface charge of nanoparticulate system. Usually large negative or positive zeta potential value required for SLNs dispersion stability as electrostatic repulsion between particles with
same charges avoids aggregation of particles (Manjunath
et al., 2005). Zeta potential data for tested FLZ-SLNs dispersions are shown in Table 2. Despite the slight differences in
zeta values -21 mV to 33 mV, all FLZ-SLNs formulae are
negatively charged which assures a good physical stability of
the formulation by electrostatic repulsion, avoiding the
occurrence of particle aggregation or coalescence. These
results were in agreement with studies on lopinavir solid lipid
nanoparticles obtained by Negi et al. (2013).
Zeta potential was slightly more negative in the SLNs prepared with Cremophor RH40 compared with the SLNs prepared with Poloxamer 407, this may be due to the chemical
nature of Poloxamer 407 that act as a steric stabilizer and
decreases the zeta potential due to shift in the electric shear
plane of particles (Kamboj et al., 2010).

Electron microscope examination
TEM photographs (data not shown) were taken to corroborate SLNs size and assess SLNs morphology. This revealed
that all prepared formulae were found to be spherical in
shape with a smooth surface and colloidal sizes with no
aggregation appeared as black dots and uniformly dispersed in the media. This indicates that the employed
method of preparation ‘hot homogenization method’ was
successfully achieve SLNs systems with uniformly distributed particles and with size range of nanometers and
these results are in agreement with findings of Ramasamy
et al. (2012).

Figure 1. In vitro release profiles of FLZ from (a) prepared SLNs and (b) relevant
SLNs gels.

In vitro drug release and kinetics study
In vitro drug release from the SLNs of FLZ was performed in
PBS (pH 5.5 at 37  C) using dialysis bag technique over 24 h
and the cumulative release percentages are illustrated in
Figure 1(a). Data of the release profiles evidences that developed SLNs were capable to release FLZ in controlled mode
as the cumulative release percentage of FLZ over 24 h ranged
from 32% to 63%. The slow release of the FLZ from most
prepared SLNs suggests homogeneous entrapment of the
drug throughout the systems, Paliwal et al. (2009) explained
similar concept and stated that controlled drug release can
be obtained when the drug is evenly dispersed in the lipid
matrix. Remarkably, the type of surfactant showed a great
impact on the FLZ release pattern from prepared SLNs.
Poloxamer 407 showed a significant increase (p value < .05)
in drug release rate from SLNs when compared with
Cremophor RH40. This could be due to the higher HLB value
of Poloxamer 407 (18–23) than the other surfactants used as
stabilizers Cremophor RH 40 (14–16) (Ekambaram & Sathali,
2011). In addition, the Poloxamer 407 has surface activity so
it reduces the interfacial tension between the SLNs and dissolution medium and decreases the aggregation of drug particles and enhances the dissolution rate of drug (El-Badry
et al., 2013). Regarding the type of lipid, Compritol 888 ATO
produced SLNs with larger particle size; higher drug entrapment and significantly (p value < .05) more prolong FLZ
release than Precirol ATO5. This finding was in consistent
with that observed by Abdelbary & Fahmy (2009) when they
used Compritol 888 ATO and Imwitor 900K as lipid component in studying the effect of different concentrations of lipids on the drug release pattern. This may be related to the
triglycerides with lipophilic long chain fatty acids which prolong the release of lipophilic drug (Hackett et al., 2013).
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Figure 2. Mean of healing percentage measured in patients at first, second,
third, and fourth week of different treatments application. Capital letters represent the significance of same treatment at different weeks. Small letters represent the significance between different treatments within the same week. Error
bars represent standard error (SE).

Moreover, the difference in lipid melting points may lead
to difference in the release profiles of drugs as indicated by
Paolicelli et al. (2009). As Precirol ATO5 has lower melting
point than Compritol 888 ATO, so that at the release experiments temperature it shows higher mobility consequently
greater cumulative drug release. On the other hand, the
results indicate the impact of lipid concentration on FLZSLNs release pattern regardless the lipid type. As by increasing the concentration of lipid from 8% to 10% w/w resulted
in corresponding decrease in the drug release. This can be
attributed to the higher lipid content encapsulating the drug,
thus reducing drug partition in the outer phase and consequently its release in the receiver media. This result was in
agreement with findings of Khalil et al. (2013). In another
words, as the lipid concentration in the SLN preparation was
increased, the thickness of the lipid coating increased
thereby increasing the length of diffusion resulting in
decrease in the drug release as shown in Figure 1(a) (Pandita
et al., 2009).
Furthermore, in vitro release profiles for the selected prepared SLNs were applied on various kinetic models (zero
order, first order, and Higuchi equations). In order to figure
out the mechanism of drug release, the rate constant as well
as the highest correlation and the best fitted line was
obtained. The release pattern of the drug from almost all
SLNs formulations were best fitted into Higuchi equation that
describes the diffusion of drug from homogenous and granular matrix systems (Vivek et al., 2007) with some fitting to
zero order equation. This explains why the drug diffuses at a
slower rate as the distance for diffusion increases, which is
referred to as Higuchi’s kinetics, i.e. matrix diffusion controlled mechanism. Considering these observations it was
concluded that all the batches of SLNs had the potential for
sustained drug delivery. This finding is in a good agreement
with the previous studies (Tiyaboonchai et al., 2007; Vivek
et al., 2007).

Differential scanning calorimetry (DSC) of FLZ SLNs
DSC is frequently used in the pharmaceutical field as a
thermal analysis technique, to provide information about

drug-excipient incompatibility in the formulation (Naidu
et al., 2004). DSC curve of pure FLZ powder, Figure 3
showed a sharp endothermic peak at 137.05  C corresponding to its melting point, indicating its characteristic crystalline nature. Bulk Compritol 888 ATO showed sharp melting
peak at (72.24  C) confirming the presence of the stable
b/form, while Precirol ATO5 at (56.41  C) which indicated
the absence of traces of impurities as shown clearly in
Figure 3. It is worthy to say that DSC curves revealed that
all FLZ-SLNs formulations possess melting point over 40  C
which indicates the solid state at room temperature (Nayak
et al., 2010). The thermograms of all examined SLNs formulae showed the absence of characteristic melting peak of
FLZ around (137.05  C) as (data not shown) concerning
SLN2 (FLZ-Compritol 888 SLNs) and SLN7 (FLZ-Precirol
ATO5 SLNs) thus suggesting that no free drug crystals were
reported in the systems. Moreover, this may indicates the
transformation of FLZ from crystalline to the amorphous
form upon loading into SLNs which may be attributed to
complete solubilization of the drug in the lipid matrix or
molecularly dispersion of the drug in the lipid matrix
(Ramasamy et al., 2012). These findings confirm the slow
release profile that we achieved in this study as the lack of
crystallinity suggests better drug dispersion and increased
drug–matrix interactions leading to the slow release kinetics
of drug from the matrix (Mahato, 2007).
Furthermore, a small increase on the onset and on the
melting temperature of the lipid when it is mixed with drug
was observed. These phenomena were previously described
€ller et al. (2008). It is worthy to note that the melting
by Mu
enthalpy values of all SLNs were lower than those of the initial lipid (data are not presented), indicating an increased
number of lattice defects in the developed FLZ-SLNs resulting in formation of amorphous regions in which the drug is
located. These results were in agreement with findings of
Prasad et al. (2010) and Mehnert & Meader (2012). This may
be explained as less energy is required for melting less
ordered crystals or amorphous solids than crystalline substances which need to overcome lattice forces as (Pople & Singh,
2006).

Preparation and characterization of FLZ SLNs topical gel
According to the best result of EE% only four formulae of
FLZ-loaded SLNs incorporated into gel formulation using 1%
Carbapol 934 as gelling agent and followed by several characterizations as:

Visual appearance, pH, and drug content
All the prepared gels of selected FLZ-SLNs formulae were
spreadable on the skin surface, white, smooth, homogenous
with semisolid consistency, and show no synerisis. The pH of
all prepared FLZ-SLNs gels was found to be 5.5–6.7 with
drug content in range 8–9 mg/1 g of gel. These properties
give the prepared gels the suitability for topical administration (Kaur & Guleri, 2013).
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Figure 3. Photographic pictures before and after treatment with (a) gel 2 and (b) gel 3.

Rheological study
The rheological properties of lipid nanoparticles affect their
potential for dermal application in a fundamental way
(Lippacher et al., 2002; Muller et al., 2002). Therefore, the
rheological behavior of gels loaded with FLZ-SLNs for topical
drug delivery was evaluated. The rheograms of all FLZ-SLNs
gels (data are not shown) revealed non-Newtonian flow
behavior with no constant viscosity (Barnes, 1997; Illinga
and Unruh, 2004; Liu et al., 2008). The flow behavior of FLZSLNs gels was also characterized by shear-thinning properties with variable thixotropy as by increasing the shear rate
the viscosity of gel consequently decreased (Khalil et al.,
2014). The combined shear thinning behavior and thixotropy
are desirable characteristics for topical formulations, as they
facilitate processing during manufacture and the flow from
the container, and improve spreading on the skin.

In addition, the applied film can gain viscosity instantaneously and thus resist running (Ammar et al., 2011; Sheth,
2007).

In vitro drug release studies
The release of FLZ from different lipid nanoparticles gels
was performed using the dialysis bag membrane
(Pandurangan et al., 2016) and the results are presented in
Figure 1(b). The results revealed that lipid nanoparticles gels
were able to release FLZ in controlled manner where the
percentage of drug released ranged from 53% to 83% after
48 h. Comparing the drug release profile of nanoparticle dispersions and their corresponding gels, the release of FLZ
from the investigated gel formulations at the end of 48 h
was slower than that of their nanoparticles dispersions.
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Figure 4. Mycological results representation of gel 2, gel 3, and CandistanV cream with pairwise comparison at each weak; capital letters represent the significance
of same treatment at different weeks and small letters represent the significance between different treatments within the same week.
R

Incorporation of nanoparticulate dispersion into gels further
decreased the drug release. This result was probably due to
the release-retarding effect of the polymeric matrix of gelling agents (Pople and Singh, 2006). As shown in
Figure 1(b), results showed that the highest drug release
was related to gel 3 and gel 4 which composed of Precirol
ATO5 as lipid content followed by Compritol 888 this is due
to the highest mono glyceride content and the lowest melting point of Precirol ATO5 lipid which may lead to a greater
mobility at the temperature used in the release experiment.
Also, the results showed that Poloxamer 407 surfactant
showed the highest release than Cremophor RH40. In addition, all investigated gels demonstrated prolonged release
characteristics following Higuchi kinetics. These results suggested that the primary release mechanism of FLZ from lipid
matrix and gel is diffusion (Muller et al., 2000; Pople &
Singh, 2006).

Clinical study

followed up by clinical and mycological examination every
week during the therapy. Furthermore, baseline photographs
were taken to the affected areas of every patient to document the pretreatment skin lesion and after week two and
four of starting therapy to evaluate the clinical efficacy and
safety of different treatment regimen.
The volunteers showed good acceptance of the formulations and reported no adverse reactions while using them or
afterwards. From Figure 2, statistical analysis for clinical
examination showed that there was a highly significant difference (p < .05) in percentage of cure from PV among all
groups treated with gel 2, gel 3, and market product
CandistanV before and after treatment. The results revealed
that the percentage of healing from fungal infection along
the four weeks for gel 2 ranged from 40% to 98%, for gel 3
ranged from 36% to 99% these results in agreement with
Karakaş et al. (2005) who found that 75% patients showed a
complete cure from PV after 4 weeks treatment with oral FLZ.
While the percentage of relief from fungal infection after four
weeks application of CandistanV cream was ranged from 22%
to 80%. From these percentages we can conclude that there
are significance difference between gel 2, gel 3 and commercial CandistanV. Furthermore, by comparing the results of
healing rate between group I and group II, the results
showed that there is no significance difference (p > .05)
between group I (treated with gel 2) and group II (treated
with gel 3).
Moreover, the clinical improvement established upon taking photographic pictures for patients infected with PV
before and after treatment with gel 2 and gel 3. The results
showed that there are great improvements of treatment
from fungal infection during 2, 3, and 4 weeks of treatment
(Figure 3).
R

R

The clinical study was performed to evaluate two formulae of
prepared FLZ-SLNs topical gels which have the lowest (50%)
and highest % (80%) drug release from gel matrix naming
gel 2 and gel 3, respectively. In addition to compare the
result with market product CandistanV cream. Thirty patients
were successfully enrolled for 4 weeks in this study to evaluate the treatment of PV. Diagnosis was done clinically based
on the typical appearance of skin lesions and confirmed by
microbiological examination. Each 10 patients enrolled randomly in group and were treated with prepared gel 2 or prepared gel 3 or market product CandistanV cream for group I,
II, and III, respectively. The treatments were applied twice
daily for 4 weeks. The volunteers in each group were
R

R

R
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Regarding the mycological culture, existing of the M. furfur
fungus represented by the mycological examination was
characterized in three main scales as follows:
Persistence (P): still positive microscopy appearance at follow up visits,
Persistence with improvement (PI): less density positive
microscopy appearance at follow up visits,
Eradication (E): complete microscopic disappearance of M.
furfur in all follow up visits.
It is obvious from Figure 4 that the percentage of cured
cases from the start to the end of the study was significantly
larger (p < .05) in group I and II than in group III. It is worthy to
say that group II show greater effect in percentage of eradication from M. furfur fungus than group I but this difference was
non-significance (p > .05). This may be attributed to the higher
drug release from SLNs as confirmed by the in vitro release
findings in the previous part of this study. In group I, at the
start of the study all the patient were infected with PV, at the
end of experiment 70% of patient showed complete eradication and 30% showed persistence with improvement from fungal infection. While in group II, at the start of the study all the
patient were infected with PV, at the end of experiment 90%
of patient showed complete eradication and 10% showed persistence with improvement from fungal infection.
However, in case of group III, at the start of the study all
the patient were infected, at the end of experiment only
30% of patient showed complete eradication and 70%
showed persistence with improvement from fungal infection.
To the best of our knowledge, there is no clinical study
regarding efficacy of topical FLZ for the treatment of PV.
However, it was proven in many studies that FLZ is highly
effective in treating PV when taken orally (Farschian et al.,
2002; Karakas et al., 2005; Yazdanpanah et al., 2007).
Although the application of oral antifungals can shorten the
duration of treatment of PV (Gupta et al., 2002), they are considered second line treatment as they can be associated with
serious adverse events as hepatotoxicity associated with oral
ketoconazole (Gupta et al., 2015; Yan et al., 2015).
In our study, topical FLZ seems to be faster and more
effective than topical CandistaneV in the cases of PV. Most of
the cases that were treated by topical FLZ-SLNs gels seemed
to be satisfied with the quick cure related (after 1 week
application) to commercial topical antifungal therapy with
average 40.0 cure rate in gel 2 formula and 36.5 cure rate in
gel 3 formula while that of CandistanV was 22.0. In addition,
there was no irritation or significant side effects with the topical FLZ formulations.
Shahid et al. (2000) study stated that the cure rate (clinical
and mycological cure) of PV ranged between 78 and 98% on
the fourth week follow up when 300 mg of FLZ was given
orally once weekly for 2 weeks . Our treatment results were
close to these findings, as we achieved clinical cure ranged
between 98 and 99% and mycological cure ranged between
70 and 90% on the fourth week of treatment, although our
treatment was applied topically. In addition, the compliance of
the patients was good, and no side effects were observed.
These results may suggest that topical FLZ in the form of SLNloaded gel can provide immediate reductions in infectivity,
and free of systemic adverse effects. The efficiency of FLZ is
R
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believed to be related to the fact that it is delivered to the stratum corneum in high concentrations which is important factor
in the treatment of PV (Haneke, 1990). However, these results
in contravene with Banerjee et al. (2012) who found that 0.5%
FLZ gel is comparable to 1%clotrimazole cream when used
topically in tinea corporis. This is may be attributed to that PV
is caused by more superficial infection usually at stratum corneum caused by Malassezia while other types of tenia are
deeper infections which involve the dermis. In addition,
enhanced drug penetration might be related to the nanometer-sized SLNs because the highly specific surface area facilitates contact of the encapsulated drug with the stratum
corneum and may favor accumulation for several hours, which
allows for sustained drug release (Jenning et al., 2000).
The majority of studies to date suggest that nanoparticles
only permeate the superficial layers of the skin in vivo and
remain in the stratum corneum (Watkinson et al., 2013).
Therefore, an enhanced bioavailability of the encapsulated
material to the skin is achieved. SLN enhance the penetration
and transport active substances particularly lipophilic agents
and thus intensify the concentration of these agents in the
skin (Muller et al., 2002).
This is may be also attributed to that the nanoparticles
show a high affinity for cellular membrane mainly due to
electrostatic interactions (Bernfild et al., 1999). Furthermore,
SLN may also offer improved drug penetrating through the
stratum corneum due to the better occlusion of the nanoparticles compared to traditional creams and gels (Wissing &
€ller, 2002).
Mu
Nanostructured lipid carriers NLC also offer possibilities in
the treatment of significant diseases as psoriasis which was
confirmed by acitretin loaded NLC in a clinical study
(Agrawal et al., 2010). Several studies that investigate the efficacy of antifungal agents for treatment of human mycoses
when incorporated with SLN concluded that when the drugs
were incorporated into an SLN there was an increased rate
and level of skin penetration, higher efficacy, and less local
side effects (Jessica et al., 2013).
Sustained release of FLZ and higher skin penetration were
possible explanations for the enhanced therapeutic efficacy
and increased tolerability of FLZ-SLNs gel in comparison to
conventional marketed CandistanV cream for topical treatment of PV.
R

R

Conclusion
PV is one of the most common cutaneous dermatologic conditions worldwide. As Malassezia species are endogenous to
the skin flora, this condition is particularly difficult to eradicate. In the meantime, there are a number of topical and
oral antifungal treatments that are effective in improving
clinical symptoms and inducing mycological cure. However,
topical therapy is the first line of treatment for PV as they
are fast-acting and well tolerated. Based on the accumulated
evidence, FLZ as antifungal agent for treating PV is only
available as oral therapy. Therefore, in this attempt, we successfully developed topical gel of FLZ loaded in SLNs prepared by hot homogenization technique followed by
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carbopol gelation. Developed FLZ-SLNs were characterized
and assessed for particle size, zeta potential, entrapment efficiency, in vitro drug release pattern, TEM, and DSC. In addition the optimized FLZ-SLN gels were subjected to
randomized, controlled clinical trial to evaluate the efficacy
of topically applied FLZ in the treatment of PV. Clinical investigations have demonstrated the superior clinical efficacy of
prepared topical FLZ-SLNs gels (Gel 2 and Gel 3) in contrast
to marketed product CandistanV in treating PV. The developed FLZ-SLNs gel exhibited improved skin penetration due
to enhanced contact between FLZ and skin resulting from
the large particle surface area and film formation.
Relapse is a widespread concern and a likely possibility.
Consequently, future work on the prepared FLZ-SLN topical
gel would be promising with respect to evaluation of effectiveness as prophylactic treatment as well as detailed regimen
(dose and duration) study which will be the forefront of our
laboratory in order to be transformed into potential marketed product.
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